Evidence map›Paper›PMID 39854413›Full record

ArticlePloS one2025

Low regulatory T-cells frequency is associated with graft rejection after small bowel transplantation: Clinical and experimental evidence.

Rodrigo Papa-Gobbi, Pablo Stringa, Maria Virginia Gentilini, Ivana Ivanoff, Mariana Machuca, Nidia Monserrat Arreola, Javier Serradilla, Karla Estefanía-Fernández, Paloma Talayero, María Velayos and 5 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rodrigo Papa-GobbiInstitute for Immunological and Pathophysiological Studies (IIFP), School of Exact Sciences, National University of La Plata, National Council of Scientific and Technical Research (CONICET), La Plata, Argentina.ORCID 0000-0002-9020-2225
Pablo StringaInstitute for Immunological and Pathophysiological Studies (IIFP), School of Exact Sciences, National University of La Plata, National Council of Scientific and Technical Research (CONICET), La Plata, Argentina.
Maria Virginia GentiliniIntestinal Failure, Rehabilitation and Transplant Unit, University Hospital Foundation Favaloro; Institute of Translational Medicine, Transplantation and Bioengineering (ImeTTyB), University Favaloro-CONICET, Buenos Aires, Argentina.
Ivana IvanoffInstitute for Immunological and Pathophysiological Studies (IIFP), School of Exact Sciences, National University of La Plata, National Council of Scientific and Technical Research (CONICET), La Plata, Argentina.
Mariana MachucaSpecial Pathology Laboratory, Faculty of Veterinary Sciences, National University of La Plata, La Plata, Buenos Aires, Argentina.
Nidia Monserrat ArreolaTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.
Javier SerradillaTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.
Karla Estefanía-FernándezTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.
Paloma TalayeroImmunology Department, 12 de Octubre University Hospital, Madrid, Spain.
María VelayosTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.
Elena Sánchez-ZapardielImmunology Department, La Paz University Hospital, Madrid, Spain.
Gabriel GondolesiIntestinal Failure, Rehabilitation and Transplant Unit, University Hospital Foundation Favaloro; Institute of Translational Medicine, Transplantation and Bioengineering (ImeTTyB), University Favaloro-CONICET, Buenos Aires, Argentina.
Ane Andrés-MorenoTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.
Martin RumboInstitute for Immunological and Pathophysiological Studies (IIFP), School of Exact Sciences, National University of La Plata, National Council of Scientific and Technical Research (CONICET), La Plata, Argentina.
Francisco Hernández-OliverosTransplant Group, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntestinal transplantation (ITx) represents the only curative option for patients with irreversible intestinal failure. Nevertheless, its rejection rate surpasses that of other solid organ transplants due to the heightened immunological load of the gut. Regulatory T-cells (Tregs) are key players in the induction and maintenance of peripheral tolerance, suggesting their potential involvement in modulating host vs. graft responses after ITx. Thus, we investigated the association of Tregs with allograft outcomes in pediatric patients and in an experimental model of small bowel transplantation.

methodsTreg frequency in human samples was analyzed by Flow cytometry (CD4+CD25highCD127-, blood samples) and immunohistochemistry (FoxP3, graft samples). Experimental allogenic-heterotopic small bowel transplantation was performed in rats and animals divided into 3 groups: non-immunosuppressant treatment, rapamycin (2 mg/kg), and tacrolimus (0.6 mg/kg) treatment. Acute cellular rejection (ACR) was diagnosed based on clinical and histological findings, graft gene expression of pro- and anti-inflammatory mediators assessed by RT-qPCR, serum IL-6 and IL-10 levels by Luminex, and Treg frequency analyzed by flow cytometry (CD4+CD25highFoxP3+).

resultsBlood samples from patients undergoing ACR exhibited a significant reduction in the Treg number compared to those with normo-functional grafts. Similarly, a diminished number of FoxP3+ cells was observed in mucosa samples with ACR. In the experimental model, rapamycin-treated animals displayed clinical and histological findings resembling those not receiving immunosuppression treatment. Notably, ACR correlated with a high CD8/CD4 ratio, loss of T-cell chimerism, mRNA upregulation of pro-inflammatory genes and diminished graft Treg frequency. In contrast, tacrolimus treatment prevented ACR and facilitate blood and graft Treg expansion. Remarkably, recipients who achieved Treg expansion within the graft remained free of ACR even after discontinuation of the immunosuppressant treatment and this phenomenon was associated with increased levels of serum IL-10.

conclusionOur clinical and experimental findings underscore the association between Treg frequency and graft rejection after ITx, advocating for strategies that promote their expansion within the gut mucosa to enhance long-term outcomes.

Indexed as

Graft RejectionIntestine, SmallT-Lymphocytes, RegulatoryAdolescentAnimalsChildChild, PreschoolFemaleForkhead Transcription FactorsHumansImmunosuppressive AgentsInterleukin-10MaleRatsSirolimusTacrolimusForkhead Transcription FactorsFOXP3 protein, humanImmunosuppressive AgentsInterleukin-10SirolimusTacrolimus

Identifiers

PMID39854413
PMCPMC11761612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.